Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News

Executive Summary

Patient-focused drug development meetings address 'soft symptoms' and reimbursement challenges as FDA says it's familiar with most concerns aired by participants.

You may also be interested in...



Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard

CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.

PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up

FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.

Pfizer Working To Resolve Sickle Cell Drug Hold Up, Dolsten Says

Rivipansel, partnered with GlycoMimetics, is one of the most advanced drugs in Pfizer’s rare disease pipeline. Phase III studies have been delayed, however, due to a manufacturing issue impacting supply.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel